Clinical therapeutic trial of aspirin and azapropazone in rheumatoid arthritis when prescribed singly and in combination
Summary A double-blind, crossover trial was carried out to assess the clinical efficacy of 3.6 g aspirin, 1200 mg azapropazone and the two drugs together in 24 adult patients with classical or definite rheumatoid disease. Pain score, morning stiffness and patients' assessment of pain were signi...
Gespeichert in:
| Veröffentlicht in: | Current medical research and opinion 1981, Vol.7 (3), p.164-167 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 167 |
|---|---|
| container_issue | 3 |
| container_start_page | 164 |
| container_title | Current medical research and opinion |
| container_volume | 7 |
| creator | Kean, W. F. Kraag, G. R. Rooney, P. J. Capell, H. A. |
| description | Summary
A double-blind, crossover trial was carried out to assess the clinical efficacy of 3.6 g aspirin, 1200 mg azapropazone and the two drugs together in 24 adult patients with classical or definite rheumatoid disease. Pain score, morning stiffness and patients' assessment of pain were significantly improved for each drug regimen when compared to placebo. There was no significant difference among the individual drug regimens. Azapropazone was the best drug regimen in terms of improving pain score, morning stiffness and patient assessment of pain, but this was not statistically significant. It is concluded that there is no justification for prescribing aspirin with azapropazone in patients with rheumatoid disease. |
| doi_str_mv | 10.1185/03007998109114257 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_7011688</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75600308</sourcerecordid><originalsourceid>FETCH-LOGICAL-c401t-de34e0176c43184b56a42ecf72992e9cdb2a4da7179e7e06cec6e668a11922753</originalsourceid><addsrcrecordid>eNp9kEuL1TAUx4Mo43X0A7gQunJXTfpKgm7k4jxgwI2uw2l6ajO0ST1Jmbnz6c14L4IIszrwf3H4MfZW8A9CqPYjrzmXWivBtRBN1cpnbCcaWZeNkvI52z36ZQ60L9mrGG85F5XS-oydSS5Ep9SO3e9n552FuUgTEqy4JWeLRC4rYSwgro6cL8APBTzASmGFh-CxyBpNuC2QgssWpYlccrG4m9AXK2G05Hociuj8z_nwp58rNiy985Bc8K_ZixHmiG9O95z9uPj6fX9V3ny7vN5_uSltw0UqB6wb5EJ2tqmFavq2g6ZCO8pK6wq1HfoKmgGkkBol8s6i7bDrFAihq0q29Tl7f9zNv__aMCazuGhxnsFj2KKRbcczJpWD4hi0FGIkHM1KbgE6GMHNI23zH-3ceXca3_oFh7-NE97sfz76zo-BFrgLNA8mwWEONBJ466Kpn5r_9E99QpjTZIHQ3IaNfOb2xHO_ATnHoe8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75600308</pqid></control><display><type>article</type><title>Clinical therapeutic trial of aspirin and azapropazone in rheumatoid arthritis when prescribed singly and in combination</title><source>Taylor & Francis</source><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Kean, W. F. ; Kraag, G. R. ; Rooney, P. J. ; Capell, H. A.</creator><creatorcontrib>Kean, W. F. ; Kraag, G. R. ; Rooney, P. J. ; Capell, H. A.</creatorcontrib><description>Summary
A double-blind, crossover trial was carried out to assess the clinical efficacy of 3.6 g aspirin, 1200 mg azapropazone and the two drugs together in 24 adult patients with classical or definite rheumatoid disease. Pain score, morning stiffness and patients' assessment of pain were significantly improved for each drug regimen when compared to placebo. There was no significant difference among the individual drug regimens. Azapropazone was the best drug regimen in terms of improving pain score, morning stiffness and patient assessment of pain, but this was not statistically significant. It is concluded that there is no justification for prescribing aspirin with azapropazone in patients with rheumatoid disease.</description><identifier>ISSN: 0300-7995</identifier><identifier>EISSN: 1473-4877</identifier><identifier>DOI: 10.1185/03007998109114257</identifier><identifier>PMID: 7011688</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Adult ; Aged ; Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - therapeutic use ; Apazone - administration & dosage ; Apazone - therapeutic use ; arthritis, rheumatoid ; Arthritis, Rheumatoid - drug therapy ; aspirin ; Aspirin - administration & dosage ; Aspirin - therapeutic use ; Azapropazone ; Clinical Trials as Topic ; Double-Blind Method ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Tablets, Enteric-Coated ; Triazines - therapeutic use</subject><ispartof>Current medical research and opinion, 1981, Vol.7 (3), p.164-167</ispartof><rights>1981 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1981</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c401t-de34e0176c43184b56a42ecf72992e9cdb2a4da7179e7e06cec6e668a11922753</citedby><cites>FETCH-LOGICAL-c401t-de34e0176c43184b56a42ecf72992e9cdb2a4da7179e7e06cec6e668a11922753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1185/03007998109114257$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1185/03007998109114257$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,776,780,4010,27900,27901,27902,59620,59726,60409,60515,61194,61229,61375,61410</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7011688$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kean, W. F.</creatorcontrib><creatorcontrib>Kraag, G. R.</creatorcontrib><creatorcontrib>Rooney, P. J.</creatorcontrib><creatorcontrib>Capell, H. A.</creatorcontrib><title>Clinical therapeutic trial of aspirin and azapropazone in rheumatoid arthritis when prescribed singly and in combination</title><title>Current medical research and opinion</title><addtitle>Curr Med Res Opin</addtitle><description>Summary
A double-blind, crossover trial was carried out to assess the clinical efficacy of 3.6 g aspirin, 1200 mg azapropazone and the two drugs together in 24 adult patients with classical or definite rheumatoid disease. Pain score, morning stiffness and patients' assessment of pain were significantly improved for each drug regimen when compared to placebo. There was no significant difference among the individual drug regimens. Azapropazone was the best drug regimen in terms of improving pain score, morning stiffness and patient assessment of pain, but this was not statistically significant. It is concluded that there is no justification for prescribing aspirin with azapropazone in patients with rheumatoid disease.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Apazone - administration & dosage</subject><subject>Apazone - therapeutic use</subject><subject>arthritis, rheumatoid</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>aspirin</subject><subject>Aspirin - administration & dosage</subject><subject>Aspirin - therapeutic use</subject><subject>Azapropazone</subject><subject>Clinical Trials as Topic</subject><subject>Double-Blind Method</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Tablets, Enteric-Coated</subject><subject>Triazines - therapeutic use</subject><issn>0300-7995</issn><issn>1473-4877</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1981</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEuL1TAUx4Mo43X0A7gQunJXTfpKgm7k4jxgwI2uw2l6ajO0ST1Jmbnz6c14L4IIszrwf3H4MfZW8A9CqPYjrzmXWivBtRBN1cpnbCcaWZeNkvI52z36ZQ60L9mrGG85F5XS-oydSS5Ep9SO3e9n552FuUgTEqy4JWeLRC4rYSwgro6cL8APBTzASmGFh-CxyBpNuC2QgssWpYlccrG4m9AXK2G05Hociuj8z_nwp58rNiy985Bc8K_ZixHmiG9O95z9uPj6fX9V3ny7vN5_uSltw0UqB6wb5EJ2tqmFavq2g6ZCO8pK6wq1HfoKmgGkkBol8s6i7bDrFAihq0q29Tl7f9zNv__aMCazuGhxnsFj2KKRbcczJpWD4hi0FGIkHM1KbgE6GMHNI23zH-3ceXca3_oFh7-NE97sfz76zo-BFrgLNA8mwWEONBJ466Kpn5r_9E99QpjTZIHQ3IaNfOb2xHO_ATnHoe8</recordid><startdate>1981</startdate><enddate>1981</enddate><creator>Kean, W. F.</creator><creator>Kraag, G. R.</creator><creator>Rooney, P. J.</creator><creator>Capell, H. A.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1981</creationdate><title>Clinical therapeutic trial of aspirin and azapropazone in rheumatoid arthritis when prescribed singly and in combination</title><author>Kean, W. F. ; Kraag, G. R. ; Rooney, P. J. ; Capell, H. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c401t-de34e0176c43184b56a42ecf72992e9cdb2a4da7179e7e06cec6e668a11922753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1981</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Apazone - administration & dosage</topic><topic>Apazone - therapeutic use</topic><topic>arthritis, rheumatoid</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>aspirin</topic><topic>Aspirin - administration & dosage</topic><topic>Aspirin - therapeutic use</topic><topic>Azapropazone</topic><topic>Clinical Trials as Topic</topic><topic>Double-Blind Method</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Tablets, Enteric-Coated</topic><topic>Triazines - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kean, W. F.</creatorcontrib><creatorcontrib>Kraag, G. R.</creatorcontrib><creatorcontrib>Rooney, P. J.</creatorcontrib><creatorcontrib>Capell, H. A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current medical research and opinion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kean, W. F.</au><au>Kraag, G. R.</au><au>Rooney, P. J.</au><au>Capell, H. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical therapeutic trial of aspirin and azapropazone in rheumatoid arthritis when prescribed singly and in combination</atitle><jtitle>Current medical research and opinion</jtitle><addtitle>Curr Med Res Opin</addtitle><date>1981</date><risdate>1981</risdate><volume>7</volume><issue>3</issue><spage>164</spage><epage>167</epage><pages>164-167</pages><issn>0300-7995</issn><eissn>1473-4877</eissn><abstract>Summary
A double-blind, crossover trial was carried out to assess the clinical efficacy of 3.6 g aspirin, 1200 mg azapropazone and the two drugs together in 24 adult patients with classical or definite rheumatoid disease. Pain score, morning stiffness and patients' assessment of pain were significantly improved for each drug regimen when compared to placebo. There was no significant difference among the individual drug regimens. Azapropazone was the best drug regimen in terms of improving pain score, morning stiffness and patient assessment of pain, but this was not statistically significant. It is concluded that there is no justification for prescribing aspirin with azapropazone in patients with rheumatoid disease.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>7011688</pmid><doi>10.1185/03007998109114257</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-7995 |
| ispartof | Current medical research and opinion, 1981, Vol.7 (3), p.164-167 |
| issn | 0300-7995 1473-4877 |
| language | eng |
| recordid | cdi_pubmed_primary_7011688 |
| source | Taylor & Francis; MEDLINE; Taylor & Francis Medical Library - CRKN |
| subjects | Adult Aged Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - therapeutic use Apazone - administration & dosage Apazone - therapeutic use arthritis, rheumatoid Arthritis, Rheumatoid - drug therapy aspirin Aspirin - administration & dosage Aspirin - therapeutic use Azapropazone Clinical Trials as Topic Double-Blind Method Drug Combinations Female Humans Male Middle Aged Tablets, Enteric-Coated Triazines - therapeutic use |
| title | Clinical therapeutic trial of aspirin and azapropazone in rheumatoid arthritis when prescribed singly and in combination |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A55%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20therapeutic%20trial%20of%20aspirin%20and%20azapropazone%20in%20rheumatoid%20arthritis%20when%20prescribed%20singly%20and%20in%20combination&rft.jtitle=Current%20medical%20research%20and%20opinion&rft.au=Kean,%20W.%20F.&rft.date=1981&rft.volume=7&rft.issue=3&rft.spage=164&rft.epage=167&rft.pages=164-167&rft.issn=0300-7995&rft.eissn=1473-4877&rft_id=info:doi/10.1185/03007998109114257&rft_dat=%3Cproquest_pubme%3E75600308%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75600308&rft_id=info:pmid/7011688&rfr_iscdi=true |